JP4667041B2 - タバコ依存症および離脱症状の治療用化合物 - Google Patents
タバコ依存症および離脱症状の治療用化合物 Download PDFInfo
- Publication number
- JP4667041B2 JP4667041B2 JP2004551866A JP2004551866A JP4667041B2 JP 4667041 B2 JP4667041 B2 JP 4667041B2 JP 2004551866 A JP2004551866 A JP 2004551866A JP 2004551866 A JP2004551866 A JP 2004551866A JP 4667041 B2 JP4667041 B2 JP 4667041B2
- Authority
- JP
- Japan
- Prior art keywords
- compounds
- adenosine
- cdp
- compound
- choline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
本発明は、タバコまたはニコチン依存症または使用の治療法または抑制法に関する。
一般に、本発明はタバコまたはニコチン依存症または使用の治療法または抑制法であって、シチジン含有化合物、シトシン含有化合物、クレアチン含有化合物、ウリジン含有化合物、アデノシン含有化合物、またはアデノシン増大(adenosine-elevating)化合物の治療的有効量を哺乳動物に投与することによる方法を特徴とする。本発明のシチジン含有化合物、シトシン含有化合物、クレアチン含有化合物、ウリジン含有化合物、アデノシン含有化合物、またはアデノシン増大化合物のいずれも、別々に投与することができる。
本明細書に記載の発明は、タバコまたはニコチン依存症または使用の治療法または抑制法を特徴とする。
驚くことに、発明者らはCDP-コリンがタバコまたはニコチンの依存症または使用の治療に有用であることを見いだし、その他の関連化合物も同様に有用であると考えている。図1のデータは、シチコリンを投与すると、プラシーボ投与中のヒト被検者に比べて、タバコの使用(1日あたりの紙巻きタバコ喫煙数で表している)が減少することを示している。
有用なシチジン含有化合物またはシトシン含有化合物には、下記の一つを含むいかなる化合物も含まれうる:シトシン、シチジン、CMP、CDP、CTP、dCMP、dCDP、およびdCTP。好ましいシチジン含有化合物にはCDP-コリンおよびシチジン5'-ジホスホコリン[ナトリウム塩]が含まれる。このシチジン含有化合物およびシトシン含有化合物のリストは、本発明を限定するためではなく、例示のために提供するものであり、前述の化合物は、例えば、Sigma Chemical Company (St. Louis, MO)から市販されている。
アデノシン含有化合物またはアデノシン増大化合物も有用な療法を提供する。有用なアデノシン含有化合物またはアデノシン増大化合物には、次のアデノシン、ATP、ADP、またはAMPの一つを含むいかなる化合物も含まれるが、これらに限定されることはない。一つの好ましいアデノシン含有化合物はS-アデノシルメチオニン(SAMe)である。
ウリジンおよびウリジン含有化合物は、PC生合成における律速因子であるCTPに変換されうるため、有用な療法を提供する(Wurtman et al., Biochemical Pharmacology 60:989-992, 2000)。有用なウリジン含有化合物には、ウリジン、UTP、UDP、またはUMPを含むいかなる化合物も含まれるが、これらに限定されることはない。好ましいウリジン含有化合物はトリアセチルウリジンである。ウリジンおよびウリジン含有化合物ならびに類縁体はヒトにおいて耐容性が高い。
クレアチンおよびクレアチン含有化合物は、脳リン脂質レベルの増大により、ATPレベルを高めることができるため、有用な療法を提供する。クレアチンおよびクレアチン含有化合物は、ヒトにおいて比較的高用量でよく耐容されることが知られている。
患者に投与するのに適した製剤または組成物を提供するために、通常の薬学習慣を用いる。経口投与が好ましいが、いかなるその他の適当な投与経路、例えば、非経口、静脈内、皮下、筋肉内、頭蓋内、眼窩内、眼内、脳室内、嚢内、脊髄内、槽内、腹腔内、鼻腔内、またはエアロゾル投与も用いることができる。治療製剤は、溶液または懸濁液の形でもよく(例えば、静脈内投与用);経口投与用に、製剤は液剤、錠剤、またはカプセル剤の形でもよく;鼻腔内製剤用に、散剤、点鼻薬、またはエアロゾルの形でもよい。
本発明のシチジン含有化合物、シトシン含有化合物、ウリジン含有化合物、クレアチン含有化合物、アデノシン含有化合物、およびアデノシン増大化合物は、単独治療薬として、互いの組み合わせで、あるいはタバコもしくはニコチンの使用もしくは依存症、またはその他の関連する身体的もしくは心理的状態の治療または抑制用の化合物を含む、物質乱用障害治療用のその他の化合物との組み合わせで投与することもできる。
本明細書において言及するすべての出版物、特許、および特許出願は、それぞれ独立の出版物または特許出願が明確かつ個別に参照として本明細書に組み込まれることが示されているのと同程度に、参照として本明細書に組み込まれる。
Claims (9)
- 哺乳動物におけるタバコまたはニコチンの依存症または使用を治療または抑制するための薬剤の調製のための、シトシン、シチジン、CMP、CDP、CTP、dCMP、dCDP、dCTP、およびCDP-コリンからなる群より選択される化合物の使用。
- 化合物がシチジンである、請求項1記載の使用。
- 化合物がCDP-コリンである、請求項1記載の使用。
- CDP-コリンを経口投与する、請求項3記載の使用。
- 化合物がCDPである、請求項1記載の使用。
- 薬剤が、長期的に投与されるための薬剤である、請求項1記載の使用。
- 哺乳動物がヒトである、請求項1記載の使用。
- ヒトが小児または青年である、請求項7記載の使用。
- ヒトが高齢者である、請求項7記載の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42497202P | 2002-11-08 | 2002-11-08 | |
PCT/US2003/035532 WO2004043229A2 (en) | 2002-11-08 | 2003-11-06 | Compounds for the treatment of tobacco dependence and withdrawal |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006508129A JP2006508129A (ja) | 2006-03-09 |
JP4667041B2 true JP4667041B2 (ja) | 2011-04-06 |
Family
ID=32312907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004551866A Expired - Fee Related JP4667041B2 (ja) | 2002-11-08 | 2003-11-06 | タバコ依存症および離脱症状の治療用化合物 |
Country Status (15)
Country | Link |
---|---|
US (2) | US7053064B2 (ja) |
EP (1) | EP1565055B1 (ja) |
JP (1) | JP4667041B2 (ja) |
CN (1) | CN100430066C (ja) |
AU (1) | AU2003291368A1 (ja) |
BR (1) | BR0316054A (ja) |
CA (1) | CA2503286C (ja) |
ES (1) | ES2427347T3 (ja) |
HK (1) | HK1083732A1 (ja) |
MX (1) | MXPA05004866A (ja) |
NO (1) | NO333979B1 (ja) |
PT (1) | PT1565055E (ja) |
RU (1) | RU2329811C2 (ja) |
UA (1) | UA83011C2 (ja) |
WO (1) | WO2004043229A2 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2425114T3 (es) * | 2000-03-16 | 2013-10-11 | The Mclean Hospital Corporation | CDP-colina y uridina para el tratamiento del abuso del acohol |
WO2005034874A2 (en) * | 2003-10-08 | 2005-04-21 | The Mclean Hospital Corporation | Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications |
AU2004317087A1 (en) * | 2003-10-08 | 2005-09-22 | The Mclean Hospital Corporation | Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids |
EP1765364A4 (en) * | 2004-06-10 | 2010-09-22 | Mclean Hospital Corp | PYRIMIDINES, SUCH AS Z: B: CYTIDINE, IN THE TREATMENT OF PATIENTS WITH BIPOLAR DISORDER |
US7737128B2 (en) * | 2004-06-10 | 2010-06-15 | The Mclean Hospital Corporation | Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
EP1784199A4 (en) * | 2004-08-11 | 2010-06-23 | Mclean Hospital Corp | COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION |
US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
CN102920019B (zh) * | 2012-11-16 | 2014-04-16 | 湖南中烟工业有限责任公司 | 一种具有减害作用的卷烟滤棒添加剂的应用方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02500372A (ja) * | 1987-10-28 | 1990-02-08 | プロ‐ニューロン,インコーポレーテッド | アシル化ウリジンおよびシチジンならびにその使用 |
US5278176A (en) * | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
US5409946A (en) * | 1991-05-29 | 1995-04-25 | Abbott Laboratories | Isoxazole, isothiazole and pyrazole compounds that enhance cognitive function |
US5472958A (en) * | 1994-08-29 | 1995-12-05 | Abbott Laboratories | 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function |
WO2000006174A1 (en) * | 1998-07-31 | 2000-02-10 | Massachusetts Institute Of Technology | Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4048316A (en) * | 1974-03-04 | 1977-09-13 | Penn Nathar W | Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning |
US4115576A (en) * | 1974-04-02 | 1978-09-19 | Penn Nathar W | Compositions and method of employing the same for inhibiting alcohol intoxication |
US4027017A (en) * | 1974-07-16 | 1977-05-31 | Chugai Seiyaku Kabushiki Kaisha | Method of treating alcoholism |
ATE37984T1 (de) * | 1983-03-01 | 1988-11-15 | Crc Ricerca Chim | Pharmazeutische zusammensetzung welche 5acetamido-3,5-dideoxy-d-glycero-dgalactononulosamins|ure cytidin monophosphat enthaelt. |
DE3400276A1 (de) | 1984-01-05 | 1985-07-18 | Ferrer Internacional S.A., Barcelona | Verwendung von cdp-cholin zur behandlung von neurologischen stoerungen |
EP0188647B1 (en) | 1985-01-24 | 1989-05-24 | NEOPHARMED S.p.A. | Acylated derivatives of cytidine-diphosphate-choline, process for their preparation and their therapeutic use |
IT1201474B (it) | 1985-10-01 | 1989-02-02 | Vincenzo Zappia | Derivati macromolecolarizzati di cdp-colina,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono |
JPS63202854A (ja) | 1987-02-17 | 1988-08-22 | Sumitomo Electric Ind Ltd | リチウム固体電解質電池 |
US7173017B1 (en) * | 1987-10-28 | 2007-02-06 | Wellstat Therapeutics Corporation | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
US4999382A (en) * | 1988-10-26 | 1991-03-12 | Massachusetts Institute Of Technology | Compositions for treating tobacco withdrawal symptoms and methods for their use |
US5179126A (en) * | 1988-10-26 | 1993-01-12 | Massachusettes Institute Of Technology | Compositions for treating tobacco withdrawl symtoms and methods for their use |
JPH08183737A (ja) | 1994-12-28 | 1996-07-16 | Advance Co Ltd | アルコール吸収抑制剤 |
US5691365A (en) * | 1995-07-18 | 1997-11-25 | University Of Kentucky Research Foundation | Nicotinic receptor antagonists in the treatment of neuropharmacological disorders |
GB9623859D0 (en) * | 1996-11-15 | 1997-01-08 | Chiroscience Ltd | Novel compounds |
US5958896A (en) * | 1997-08-08 | 1999-09-28 | The Mclean Hospital | Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure |
US6153653A (en) * | 1997-11-26 | 2000-11-28 | Protarga, Inc. | Choline compositions and uses thereof |
US5977174A (en) * | 1997-11-26 | 1999-11-02 | Neuromedica, Inc. | Cholinergic compositions and uses thereof |
ES2425114T3 (es) * | 2000-03-16 | 2013-10-11 | The Mclean Hospital Corporation | CDP-colina y uridina para el tratamiento del abuso del acohol |
ES2170649B1 (es) | 2000-03-29 | 2003-06-16 | Ferrer Int | Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica. |
US6277855B1 (en) * | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
US6964969B2 (en) * | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
US20030114415A1 (en) * | 2001-12-14 | 2003-06-19 | Wurtman Richard J. | Compositions and methods for treating and preventing memory impairment using citicoline |
AU2003241281A1 (en) * | 2002-03-27 | 2003-10-13 | The Regents Of The University Of California | Synergy of dopamine d2 and adenosine a2 receptors activates pka signaling via beta/gamma dimers |
CN100563660C (zh) * | 2002-12-20 | 2009-12-02 | 麦克莱恩医院 | 用于正常化睡眠/觉醒周期的化合物 |
-
2003
- 2003-11-06 BR BR0316054-8A patent/BR0316054A/pt not_active Application Discontinuation
- 2003-11-06 RU RU2005117631/14A patent/RU2329811C2/ru not_active IP Right Cessation
- 2003-11-06 US US10/703,695 patent/US7053064B2/en not_active Expired - Lifetime
- 2003-11-06 EP EP03768760.5A patent/EP1565055B1/en not_active Expired - Lifetime
- 2003-11-06 AU AU2003291368A patent/AU2003291368A1/en not_active Abandoned
- 2003-11-06 CA CA2503286A patent/CA2503286C/en not_active Expired - Fee Related
- 2003-11-06 UA UAA200504725A patent/UA83011C2/ru unknown
- 2003-11-06 MX MXPA05004866A patent/MXPA05004866A/es active IP Right Grant
- 2003-11-06 PT PT37687605T patent/PT1565055E/pt unknown
- 2003-11-06 WO PCT/US2003/035532 patent/WO2004043229A2/en active Application Filing
- 2003-11-06 ES ES03768760T patent/ES2427347T3/es not_active Expired - Lifetime
- 2003-11-06 JP JP2004551866A patent/JP4667041B2/ja not_active Expired - Fee Related
- 2003-11-06 CN CNB2003801085134A patent/CN100430066C/zh not_active Expired - Fee Related
-
2005
- 2005-05-12 NO NO20052347A patent/NO333979B1/no not_active IP Right Cessation
-
2006
- 2006-02-22 HK HK06102369.3A patent/HK1083732A1/xx not_active IP Right Cessation
- 2006-05-25 US US11/440,488 patent/US7601701B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02500372A (ja) * | 1987-10-28 | 1990-02-08 | プロ‐ニューロン,インコーポレーテッド | アシル化ウリジンおよびシチジンならびにその使用 |
US5409946A (en) * | 1991-05-29 | 1995-04-25 | Abbott Laboratories | Isoxazole, isothiazole and pyrazole compounds that enhance cognitive function |
US5278176A (en) * | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
US5472958A (en) * | 1994-08-29 | 1995-12-05 | Abbott Laboratories | 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function |
WO2000006174A1 (en) * | 1998-07-31 | 2000-02-10 | Massachusetts Institute Of Technology | Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases |
Also Published As
Publication number | Publication date |
---|---|
CA2503286C (en) | 2011-08-30 |
MXPA05004866A (es) | 2005-11-04 |
US7601701B2 (en) | 2009-10-13 |
PT1565055E (pt) | 2013-09-16 |
ES2427347T3 (es) | 2013-10-30 |
NO333979B1 (no) | 2013-11-04 |
WO2004043229A2 (en) | 2004-05-27 |
EP1565055A2 (en) | 2005-08-24 |
NO20052347L (no) | 2005-06-06 |
US7053064B2 (en) | 2006-05-30 |
CN1735343A (zh) | 2006-02-15 |
AU2003291368A1 (en) | 2004-06-03 |
CA2503286A1 (en) | 2004-05-27 |
CN100430066C (zh) | 2008-11-05 |
HK1083732A1 (en) | 2006-07-14 |
US20060217344A1 (en) | 2006-09-28 |
BR0316054A (pt) | 2005-09-20 |
RU2329811C2 (ru) | 2008-07-27 |
AU2003291368A8 (en) | 2004-06-03 |
WO2004043229A3 (en) | 2004-08-26 |
EP1565055B1 (en) | 2013-06-12 |
UA83011C2 (ru) | 2008-06-10 |
JP2006508129A (ja) | 2006-03-09 |
US20040167093A1 (en) | 2004-08-26 |
RU2005117631A (ru) | 2006-01-20 |
EP1565055A4 (en) | 2010-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011102319A (ja) | 睡眠/覚醒サイクルの正規化のための化合物 | |
US7601701B2 (en) | Compounds for the treatment of tobacco dependence and withdrawal | |
ES2332669T3 (es) | Uso de uridina en combinacion con colina para el tratamiento de trastornos de la memoria. | |
ES2236910T3 (es) | Composicion para controlar trastornos del estado de animo en individuos sanos. | |
KR20080091767A (ko) | (테노포비어 및 라미뷰딘과 같은) 뉴클레오티드 역전사효소억제제 및 뉴클레오시드 역전사효소 억제제를 투여 단위의상이한 부분에 포함하는 약제학적 조합물 | |
CA2384840A1 (en) | Use of pramipexole as a treatment for cocaine craving | |
US20040162322A1 (en) | Use of pramipexole as a treatment for cocaine craving | |
US20230293567A1 (en) | Product and method for increasing uridine concentration in blood plasma | |
US7947661B2 (en) | Compounds for the treatment of marihuana dependence, withdrawal, and usage | |
US6369041B2 (en) | Oral combinations of hydroxocobalamin and folic acid | |
Blackwell | Antidepressant drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061030 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100308 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100607 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100705 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101102 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20101102 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20101129 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101215 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140121 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4667041 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |